Terminated PHASE4 INTERVENTIONAL 1-arm NCT00476619

Erythropoietin in Radiocontrast Induced Nephropathy (ERIN) Trial (ERIN)

Sponsor: Brigham and Women's Hospital

Updated 6 times since 2017 Last updated: Apr 2, 2009 Started: Sep 30, 2004 Primary completion: Nov 30, 2007 Completion: Jun 30, 2008

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

The exclusion criteria were stringent and enrollment was slow.

Other terminated trials from Brigham and Women's Hospital

See all terminations from Brigham and Women's Hospital

Other Contrast Induced Nephropathy trials with similar outcome

Browse all Contrast Induced Nephropathy trials

This PHASE4 trial investigates Contrast Induced Nephropathy and is currently terminated or withdrawn. Brigham and Women's Hospital leads this study, which shows 6 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE4

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE4

First recorded

Sep 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Brigham and Women's Hospital
Ortho Biotech Products, L.P.

Data source: Brigham and Women's Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States